NIH awards 12 research grants totaling $5 million for Tβ4 research

REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that National Institutes of Health (NIH) has awarded 12 research grants totaling over $5,000,000 for the study of Tβ4 in 2009/2010. Many of these grants will be going to collaborators with whom RegeneRx is working to understand its numerous biological activities and capabilities in medical indications, including the role of Tβ4 as an anti-inflammatory agent in tissue regeneration and its promotion of stem cell maturation. Research on the identification and characterization of the key factors needed to trigger stem cell differentiation and maturation are among the most active areas of medical research and are believed to be fundamental to the future development of breakthrough therapeutic agents. Additional research projects are focused on understanding the mechanisms of action and role of Tβ4 in diverse areas of biomedicine ranging from cardiovascular disease and kidney fibrosis to neurological disorders and memory. The research funded by these grants will advance our understanding of the basic mechanisms of Tβ4’s actions and its clinical potential.

“NIH grants are peer-reviewed with fewer than 20% of applicants receiving this prestigious funding. These awards demonstrate the high value that the scientific community and NIH place on both thymosin β4 technology and the research teams exploring its potential”

“NIH grants are peer-reviewed with fewer than 20% of applicants receiving this prestigious funding. These awards demonstrate the high value that the scientific community and NIH place on both thymosin β4 technology and the research teams exploring its potential,” stated Dr. Hynda K. Kleinman, a scientist at the NIH for 31 years, who has served on numerous grant review panels, and currently a consultant for RegeneRx and a member of its scientific advisory board.